Anti-CX3CL1 mAb therapy efficiently suppressed the infiltration of BALF M1 macrophages in the mouse model of RA-ILD, and therefore, this therapy combined with anti-fibrotic drugs may have a more robust therapeutic effect on lung fibrosis. Here, CX3CL1 is linked to interstitial lung disease.